PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $214,118 | -6.4% | 6,183 | +11.7% | 0.00% | – |
| Q2 2023 | $228,706 | +26.4% | 5,535 | +34.3% | 0.00% | – |
| Q4 2022 | $180,914 | -33.0% | 4,122 | -17.0% | 0.00% | – |
| Q3 2022 | $270,000 | -0.7% | 4,964 | +5.8% | 0.00% | – |
| Q2 2022 | $272,000 | -70.7% | 4,693 | -61.5% | 0.00% | – |
| Q1 2022 | $929,000 | +23.4% | 12,182 | +1.1% | 0.00% | – |
| Q4 2021 | $753,000 | -12.7% | 12,046 | -20.8% | 0.00% | – |
| Q3 2021 | $863,000 | -10.5% | 15,211 | -1.7% | 0.00% | – |
| Q2 2021 | $964,000 | +6.9% | 15,471 | +17.6% | 0.00% | -100.0% |
| Q1 2021 | $902,000 | +7.3% | 13,154 | +11.9% | 0.00% | 0.0% |
| Q4 2020 | $841,000 | +257.9% | 11,758 | +195.3% | 0.00% | – |
| Q3 2020 | $235,000 | -23.5% | 3,982 | -25.2% | 0.00% | – |
| Q2 2020 | $307,000 | +448.2% | 5,326 | +208.0% | 0.00% | – |
| Q1 2020 | $56,000 | -80.8% | 1,729 | -73.1% | 0.00% | – |
| Q4 2019 | $292,000 | +59.6% | 6,431 | +33.1% | 0.00% | – |
| Q3 2019 | $183,000 | +13.7% | 4,832 | +30.2% | 0.00% | – |
| Q2 2019 | $161,000 | -90.1% | 3,710 | -91.3% | 0.00% | -100.0% |
| Q1 2019 | $1,627,000 | -2.7% | 42,750 | +10.0% | 0.00% | -50.0% |
| Q4 2018 | $1,672,000 | -13.5% | 38,870 | -1.1% | 0.00% | 0.0% |
| Q3 2018 | $1,932,000 | +57.7% | 39,292 | +2.8% | 0.00% | +100.0% |
| Q2 2018 | $1,225,000 | -18.6% | 38,228 | -20.8% | 0.00% | 0.0% |
| Q1 2018 | $1,504,000 | +14.6% | 48,273 | +67.9% | 0.00% | 0.0% |
| Q4 2017 | $1,312,000 | -6.0% | 28,747 | -22.7% | 0.00% | 0.0% |
| Q3 2017 | $1,396,000 | -13.1% | 37,180 | +10.4% | 0.00% | -50.0% |
| Q2 2017 | $1,606,000 | -13.5% | 33,671 | -17.3% | 0.00% | 0.0% |
| Q1 2017 | $1,857,000 | -29.9% | 40,724 | -51.0% | 0.00% | -33.3% |
| Q4 2016 | $2,649,000 | -59.6% | 83,156 | -56.6% | 0.00% | -57.1% |
| Q3 2016 | $6,555,000 | +1.4% | 191,546 | -0.1% | 0.01% | 0.0% |
| Q2 2016 | $6,467,000 | -46.0% | 191,728 | -15.1% | 0.01% | -46.2% |
| Q1 2016 | $11,966,000 | -24.6% | 225,843 | +9.3% | 0.01% | -31.6% |
| Q4 2015 | $15,864,000 | +69.5% | 206,607 | -9.2% | 0.02% | +46.2% |
| Q3 2015 | $9,357,000 | -18.6% | 227,666 | +40.0% | 0.01% | 0.0% |
| Q2 2015 | $11,502,000 | -14.4% | 162,633 | +7.5% | 0.01% | -18.8% |
| Q1 2015 | $13,436,000 | -20.3% | 151,223 | -20.4% | 0.02% | -15.8% |
| Q4 2014 | $16,853,000 | -4.0% | 190,090 | +5.0% | 0.02% | -5.0% |
| Q3 2014 | $17,554,000 | -6.2% | 181,114 | -11.1% | 0.02% | -4.8% |
| Q2 2014 | $18,716,000 | +35.4% | 203,753 | +3.2% | 0.02% | +16.7% |
| Q1 2014 | $13,822,000 | -3.3% | 197,486 | -20.5% | 0.02% | -10.0% |
| Q4 2013 | $14,288,000 | -2.5% | 248,529 | -18.5% | 0.02% | -13.0% |
| Q3 2013 | $14,658,000 | +62.0% | 304,890 | -2.3% | 0.02% | +43.8% |
| Q2 2013 | $9,048,000 | – | 312,008 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |